HOME >> MEDICINE >> NEWS
MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis

Wellesley Hills, MA, April 11 -- MacroChem Corporation (OTCBB: MACM.OB) announced the completion of patient enrollment in a 40 patient U.S. multi-center open label Phase II efficacy study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). EcoNail is the company's patented lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA.

Patients participating in the study, which is being conducted under MacroChem's U.S. Investigational New Drug application filed with the FDA, will receive 48 weeks of treatment and will undergo efficacy assessments using standard criteria of nail appearance and mycology. However, the Company will collect and evaluate 24-week interim data later this year. This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase III as soon as possible.

"Full enrollment in this Phase II study is an important milestone in advance of our planned interim assessment later this year. An earlier than originally intended evaluation of clinical data from a subset of patients treated for 24 weeks may be conducted to facilitate planning for potential future clinical development", stated Robert DeLuccia, President and CEO of MacroChem. He continued, "I believe that the recent precedent-setting deal activity for topical nail fungus products in clinical development by two major international pharmaceutical companies reflects the high level of interest in the marketplace for new treatments for onychomycosis."

DeLuccia further noted: "If we can develop a topical therapy without the treatment-limiting side effects experienced with the current market-leading oral products and with better efficacy than the only currently available topical product, we believe this c
'"/>

Contact: Rachel Anscher
ranscher@investorrelationsgroup.com
212-825-3210
MacroChem
11-Apr-2007


Page: 1 2

Related medicine news :

1. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
2. Acrux completes enrollment in key phase 2 trial
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
6. Comparison of obstetric outcomes between on-call and patients own obstetricians
7. Test project of patient-centered medical home model endorsed by American College of Physicians
8. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
9. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
10. Happier hospitals means healthier patients
11. Many heart attack patients still not getting emergency clot-busting treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/14/2019)... ... 2019 , ... GreenTheVoteOk , one of the most reliable online resource ... the most relevant and important developments in the fast-changing world of legalized CBD. ... people across the world suffering from different difficult-to-treat ailments, people need to identify brands ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace injuries cost ... to solve injury risks which lead to musculoskeletal disorders (MSDs). , Starting ... by the team at Soter Analytics helps avoid ergonomic injury by ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... September 11-14 in Minneapolis at the Mall of America Radisson Blu. Four experts ... faculty members for the high-profile, knee-focused conference, which brings together more than 100 ...
(Date:9/11/2019)... ... 2019 , ... Autopsies don’t lie. They report the causes of death ... permanently harms the heart. It increases risks of heart attack and death. ... the damage occurs. , An August 1, 2019 article in U.S. ...
(Date:9/11/2019)... ... September 11, 2019 , ... Executives at health systems ... change in the healthcare industry over the past several years has been intense. For ... The future of healthcare in America will depend largely on how these executives respond. ...
Breaking Medicine News(10 mins):
(Date:9/18/2019)... ... September 18, 2019 , ... Henry Ford e-Home ... care via Henry Ford’s e-Home Care program. Achieving monthly readmission rates as low ... for the first six months of 2019 by 45% compared with the prior ...
(Date:9/18/2019)... ... September 18, 2019 , ... U.S. Dermatology Partners was ... water swim Saturday, September 14th. The event took place at Lake Ray Hubbard ... and Jim Montgomery. The money raised helps fund phase 1 clinical trials ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... new, more effective therapeutic agents to stop the progressive destruction of joint cartilage ... have dawned, says Miami-based hand and upper limb orthopedic surgeon Alejandro Badia, ...
Breaking Medicine Technology:
Cached News: